Birmingham-based Rem3dy Health has secured a strategic investment from Hikma Ventures, the corporate venture capital arm of London-listed pharmaceutical group Hikma Pharmaceuticals PLC.
The company, behind the Nourished brand, has not disclosed the size of the investment. It follows a year in which Rem3dy Health reported revenue growth of 61% to £10.2m.
Rem3dy Health said it has continued to expand through UK retailers including Boots, Costco and Holland & Barrett, alongside a growing network of international commercial partners.
The deal builds on a recently announced exclusive commercial partnership between the two companies.
Under that agreement, Hikma will introduce Rem3dy’s 3D-printed nutritional supplements across seven markets in the Middle East and North Africa.
Initial launches are planned for the UAE, Saudi Arabia and Jordan in the first quarter of 2027.
Further expansion is planned across Qatar, Kuwait, Oman and Bahrain, alongside opportunities in additional regional markets.
The Nourished products developed for Hikma will be manufactured in the UK and will initially focus on cognitive wellbeing, gut health, hair and nail health, and sleep.
The range will form the foundation of Hikma’s vitamins, minerals and supplements portfolio, according to the release.
For Hikma, the investment is its first in the health and wellness innovation sector.
Rem3dy Health was founded in 2019 by entrepreneur Melissa Snover.
It has developed a manufacturing platform combining 3D printing, material science and artificial intelligence to produce nutritional supplements at commercial scale.
The technology is protected by a portfolio of 29 patents and allows multiple active ingredients to be combined into a single seven-layer nutritional gummy.
The company said it has invested significantly in developing and scaling its manufacturing capabilities in the West Midlands.
Snover said: “Having Hikma invest in Rem3dy as well as partner with us commercially is particularly meaningful because it connects capital investment with a genuine route to market.
“We have spent the past seven years developing our technology, building our intellectual property and scaling our manufacturing capabilities here in Birmingham.”
Lana Ghanem, vice president corporate development at Hikma Pharmaceuticals and managing director of Hikma Ventures, said: “At Hikma, we are constantly looking for innovative companies that are shaping the future of healthcare.
“This investment reflects Hikma Ventures’ strategy of backing high-growth healthcare businesses that not only have significant commercial potential but can also create strategic value across Hikma’s businesses and markets.”
Hikma describes itself as a multinational pharmaceutical company with operations across North America, the Middle East and North Africa, and Europe.
Hikma Ventures was established in 2015 as the group’s corporate venture capital arm.
How Rem3dy Health founder is building a truly personal business